[go: up one dir, main page]

PE20091095A1 - Moduladores de gamma secretasa - Google Patents

Moduladores de gamma secretasa

Info

Publication number
PE20091095A1
PE20091095A1 PE2008002022A PE2008002022A PE20091095A1 PE 20091095 A1 PE20091095 A1 PE 20091095A1 PE 2008002022 A PE2008002022 A PE 2008002022A PE 2008002022 A PE2008002022 A PE 2008002022A PE 20091095 A1 PE20091095 A1 PE 20091095A1
Authority
PE
Peru
Prior art keywords
pyridine
pirrolo
fluorobenzyl
imidazol
aryl
Prior art date
Application number
PE2008002022A
Other languages
English (en)
Inventor
Thomas Bara
Duane Burnett
Jhon Clader
Hubert Josien
Dmitri Pissarnitski
Zhiqiang Zhao
Xianhai Huang
Anandan Palani
Jun Qin
Robert G Aslanian
Zhaoning Zhu
William J Greenlee
Xiaohong Zhu
Mihirbaran Mandal
Pawan Dhondi
Troy Mccracken
Wei Zhou
Chad E Bennett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20091095A1 publication Critical patent/PE20091095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE FORMULA (I) DONDE R1 ES ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R2 ES INDOLINA, PIRROLO[3,2-c]PIRIDINA, PIRROLO[2,3-b]PIRIDINA, ENTRE OTROS; R3 ES -ARIL, -HETEROARIL, CICLOALQUILO, ENTRE OTROS; R4 ES -ARILALCOXI, -ARILALQUILAMINO, ARILO, ENTRE OTROS; L ES ENLACE DIRECTO, -O-, -N(R5)-, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS SELECCIONADOS: 1-(4-FLUOROBENCIL)-4-(4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL)INDOLINA, 1-(4-FLUOROBENCIL)-4-(4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL)-1H-PIRROLO[3,2c]PIRIDINA, 1-(4-FLUOROBENCIL)-4-(4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL)-1H-PIRROLO[2,3b]PIRIDINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE GAMMA SECRETASA, SIENDO UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, SINDROME DE DOWN, DEFICIENCIA COGNITIVA SUAVE, ENTRE OTROS
PE2008002022A 2007-12-06 2008-12-05 Moduladores de gamma secretasa PE20091095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99283907P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
PE20091095A1 true PE20091095A1 (es) 2009-07-25

Family

ID=40351934

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002022A PE20091095A1 (es) 2007-12-06 2008-12-05 Moduladores de gamma secretasa

Country Status (13)

Country Link
US (1) US8450343B2 (es)
EP (1) EP2229381A1 (es)
JP (1) JP2011506335A (es)
KR (1) KR20100094554A (es)
CN (1) CN101939315A (es)
AR (1) AR069635A1 (es)
AU (1) AU2008333865A1 (es)
CA (1) CA2707712A1 (es)
IL (1) IL206172A0 (es)
MX (1) MX2010006243A (es)
PE (1) PE20091095A1 (es)
TW (1) TW200930366A (es)
WO (1) WO2009073777A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
KR20110082189A (ko) 2008-11-06 2011-07-18 아스트라제네카 아베 아밀로이드 베타의 조절제
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
KR20110113197A (ko) 2009-02-06 2011-10-14 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 헤테로사이클릭 화합물
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CN102333777B (zh) * 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
EP2427453B1 (en) 2009-05-07 2013-07-17 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
US20120142672A1 (en) * 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
CN102482227A (zh) 2009-07-15 2012-05-30 杨森制药公司 作为γ分泌酶调节剂的取代的三唑和咪唑衍生物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
IN2013CN01326A (es) * 2010-07-22 2015-04-24 Kowa Co
EP2611805A1 (en) * 2010-09-02 2013-07-10 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
US8912181B2 (en) 2011-01-07 2014-12-16 Taiho Pharmaceutical Co., Ltd. Bicyclic compound or salt thereof
CA2834101A1 (en) * 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel indole or indazole derivative or salt thereof
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
JP6068464B2 (ja) * 2011-07-15 2017-01-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド γ−セクレターゼ調節剤としての新規な置換インドール誘導体
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013066740A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Gamma secretase modulators
MX355164B (es) 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
CA2887887C (en) 2012-10-31 2020-08-25 Raqualia Pharma Inc. Pyrazolopyridine derivatives as ttx-s blockers
EP3323821A1 (en) 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
MX2015005506A (es) 2012-11-08 2015-08-05 Pfizer Compuestos heteroaromaticos como ligandos d1 de dopamina.
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
CN104936958B (zh) 2013-01-17 2019-07-26 詹森药业有限公司 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物
PL3080125T3 (pl) * 2013-12-12 2019-06-28 Chong Kun Dang Pharmaceutical Corp. Pochodne azaindolu jako selektywne inhibitory deacetylazy histonowej (HDAC) i zawierające je kompozycje farmaceutyczne
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
WO2016176457A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
RS61688B1 (sr) 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
CN111670189A (zh) 2018-01-31 2020-09-15 爱尔兰詹森科学公司 对rsv具有活性的环烷基取代的吡唑并嘧啶
MA52348A (fr) 2018-04-23 2021-03-03 Janssen Sciences Ireland Unlimited Co Composés hétéroaromatiques ayant une activité contre vrs
US20220048987A1 (en) * 2020-08-13 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Method of treatment to prevent or reverse age-associated inflammation, cognitive decline, and neurodegeneration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026712A (en) * 1985-06-05 1991-06-25 Schering Ag Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents
US4937258A (en) * 1989-09-12 1990-06-26 Berlex Laboratories, Inc. Pyrrolo[1,2-c]imidazolone derivatives as PDE inhibitors
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CA2525547C (en) 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2005063756A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy

Also Published As

Publication number Publication date
EP2229381A1 (en) 2010-09-22
JP2011506335A (ja) 2011-03-03
US20110015190A1 (en) 2011-01-20
IL206172A0 (en) 2010-12-30
CA2707712A1 (en) 2009-06-11
TW200930366A (en) 2009-07-16
KR20100094554A (ko) 2010-08-26
MX2010006243A (es) 2010-08-31
AU2008333865A1 (en) 2009-06-11
WO2009073777A1 (en) 2009-06-11
AU2008333865A2 (en) 2010-07-29
US8450343B2 (en) 2013-05-28
AR069635A1 (es) 2010-02-10
CN101939315A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
PE20091095A1 (es) Moduladores de gamma secretasa
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20090718A1 (es) Derivados de espiroindolinona
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
PE20121695A1 (es) 5-alquinil-pirimidinas
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
TW200612936A (en) Indole derivatives
PE20040168A1 (es) Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20070790A1 (es) Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20090712A1 (es) Moduladores de la gamma secretasa
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina

Legal Events

Date Code Title Description
FD Application declared void or lapsed